ClinicalTrials.gg

Program

VSA012

A development code.

Its studies are mostly in Hemoglobinuria, Paroxysmal, led by 2 companies.

Furthest: phase 3, since Sep 4, 20263 company-led studies, 3 open or runningNext primary completion: Feb 28, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bisirna Therapeutics (Suzhou)22 open or runningphase 3since Sep 4, 2026Dec 29, 2024Sep 30, 2027phase 3 · NCT07816237
Bisirna Therapeutics Pte.11 open or runningphase 1since Feb 17, 2025Feb 17, 2025Feb 28, 2027phase 1 · NCT06848296

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 29, 2024First study: phase 1 study in Healthy VolunteersNew to Bisirna Therapeutics (Suzhou)Bisirna Therapeutics (Suzhou) · NCT06766929 · 40 enrolled · China
  2. Feb 17, 2025Bisirna Therapeutics Pte.'s first study: phase 1 study in Hemoglobinuria, ParoxysmalNew to Bisirna Therapeutics Pte.Bisirna Therapeutics Pte. · NCT06848296 · 50 enrolled · China
  3. Sep 4, 2026Phase 3 study in Hemoglobinuria, ParoxysmalPhase 3 reachedBisirna Therapeutics (Suzhou) · NCT07816237 · 70 planned · China

Ahead

  1. Feb 28, 2027Primary completion: phase 1 study in Hemoglobinuria, ParoxysmalBisirna Therapeutics Pte. · NCT06848296
  2. Sep 30, 2027Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalBisirna Therapeutics (Suzhou) · NCT07816237

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07816237Hemoglobinuria, Paroxysmal · China3Not yet recruitingBisirna Therapeutics (Suzhou)Sep 30, 202770
NCT06848296Hemoglobinuria, Paroxysmal · China1Active, not recruitingBisirna Therapeutics Pte.Feb 28, 202750
NCT06766929Healthy Volunteers · China1Active, not recruitingBisirna Therapeutics (Suzhou)Aug 202640

How it is read

Names in the registry

  • “VSA012”, 3 entries

Codes read as this program: VSA012.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.